Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) — Stock Score Summary

Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) has a MoatMap StockRank of 31/100 based on Quality (56/100), Value (31/100), and Momentum (31/100) factor scores. The current signal is SELL. While Tigermed is a leading clinical CRO in China, the escalating geopolitical tensions and the US Biosecure Act create a structural headwind that outweighs domestic demand, making it an asymmetric risk to the downside.

Hangzhou Tigermed Consulting Co., Ltd. is a leading China-based contract research organization (CRO) providing comprehensive professional services for biopharmaceutical and medical device R&D. The company commands a dominant market share in China's clinical trial market, offering a full-suite platform from Phase I to IV trials. Its extensive hospital network and strong regulatory track record establish a formidable competitive moat, facilitating its expansion into global clinical markets.

Key Financial Metrics

Price$5.90
Market Cap$5.0B
P/E (TTM)42.66
P/E (Forward)25.65
Price/Book1.59
Return on Equity4.2%
Return on Invested Capital4.3%
Debt/Equity7.01
Gross Margin26.6%
Operating Margin9.9%
Revenue Growth15.2%
Dividend Yield0.8%
Free Cash Flow$23M

Hangzhou Tigermed Consulting Co., Ltd operates in the Diagnostics & Research industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Hangzhou Tigermed Consulting Co., Ltd’s (300347.SZ) StockRank?
MoatMap’s StockRank for Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) is 31/100, with a Sell signal. It is a composite of Quality (56), Value (31), and Momentum (31) factor ranks across MoatMap’s 19,000+ stock universe.
Does Hangzhou Tigermed Consulting Co., Ltd have an economic moat?
Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) has a Quality factor score of 56/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Hangzhou Tigermed Consulting Co., Ltd a buy, hold, or sell?
MoatMap’s current signal for Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) is Sell, based on a StockRank of 31/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Hangzhou Tigermed Consulting Co., Ltd in?
Hangzhou Tigermed Consulting Co., Ltd (300347.SZ) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).
Browse all ranked stocks300347.SZ deep dive reportAI ChampionsHow we score stocksSense-check another stock